Dr. Liguori is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
3700 Beverly Blvd
Los Angeles, CA 90004Phone+1 310-423-3177
Education & Training
Lewis Katz School of Medicine at Temple UniversityClass of 2024
Publications & Presentations
PubMed
- 5 citationsPreclinical studies with ONC201/TIC10 and lurbinectedin as a novel combination therapy in small cell lung cancer (SCLC).Nicholas R Liguori, Ashley Sanchez Sevilla Uruchurtu, Leiqing Zhang, Abbas E Abbas, Young S Lee
American Journal of Cancer Research. 2022-01-01 - 10 citationsTherapeutic Targeting of Autophagy in Pancreatic Ductal AdenocarcinomaAlexander G. Raufi, Nicholas R. Liguori, Lindsey Carlsen, Cassandra Parker, Liz J. Hernandez Borrero
Frontiers in Pharmacology. 2021-11-30 - 7 citationsAbsence of Biomarker-Driven Treatment Options in Small Cell Lung Cancer, and Selected Preclinical Candidates for Next Generation Combination Therapies.Nicholas R. Liguori, Young Lee, William Borges, Lanlan Zhou, Christopher G. Azzoli
Frontiers in Pharmacology. 2021-08-31
Abstracts/Posters
- Abstract #5746: Synergistic activity of Lurbinectidin plus ONC201 in SCLC is associated with ATF4, CHOP and pChk1 inductionNicholas R Liguori, Ashley Sanchez Sevilla Uruchurtu, Leiqing Zhang, Abbas E Abba, Young S Lee, Lanlan Zhou, Varun V Prabhu, Christopher G Azzoli, Wafik S El-Deiry, AACR Annual Meeting 2022, New Orleans, LA, 4/13/2022
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
